Veradermics (MANE) Change in Account Payables (2025 - 2026)

Veradermics posted quarterly Change in Account Payables of -$1.1 million for Q1 2026, down 53.79% year-on-year from -$2.3 million in Q1 2025, and down 53.79% on a QoQ basis from -$686000.0 in Q1 2025.

Veradermics (MANE) has 2 years of Change in Account Payables data on file, last reported at -$1.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -3.26 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 35.60 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Veradermics 2.29 Bn 2.29 Bn - -1.06 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -1.06 Mn
Mar 31, 2026 -1.06 Mn
Mar 31, 2025 -686,000.00
Mar 31, 2025 -686,000.00